CAP ’13 – THE Pathologists’ Meeting – October 13 – 16, 2013™
HomeVirtual CatalogLearningSpecial EventsConnection Café & ExhibitsGeneral InfoTravel & HotelExhibitors
Learning

Courses by Topic


Courses by Day


Faculty Index

NEW  AP114  HER2 Testing in Gastric and Gastroesophageal Junction Cancers: A New Therapeutic Target and Diagnostic Challenge

Monday, October 14
2:00–4:00 PM
2.0 CME CREDITS

Patient Care Medical Knowledge

The recent approval of trastuzumab for advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma offers a much-needed therapeutic option; however, it also creates challenges in the pathology laboratory. Accurate HER2 testing is critical to determine which patients are eligible for this life-prolonging therapy. The presenters will provide the results of the first clinical trial to demonstrate a benefit of trastuzumab in gastric/GEJ adenocarcinoma. This course also will review the interpretive guidelines for HER2 assessment in gastric/GEJ adenocarcinoma, comparing them to breast cancer, and will conclude with a review of illustrative cases that can be used by participants for self-assessment of knowledge gained.

You will learn to:

Faculty
David G. Hicks, MD, FCAP
Christa L. Whitney-Miller, MD

 

 

 

 

Register Now Course Materials